Evidence map›Paper›PMID 37764065›Full record

ArticleMicroorganisms2023

Seroprevalence Study of Conserved Enterotoxigenic

Frederick Matthew Kuhlmann, Vadim Grigura, Timothy J Vickers, Michael G Prouty, Lora L Iannotti, Sherlie Jean Louis Dulience, James M Fleckenstein

Open access · goldAbstract read
In one paragraph

Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Frederick Matthew KuhlmannDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine in Saint Louis, Saint Louis, MO 63110, USA.
Vadim GriguraDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine in Saint Louis, Saint Louis, MO 63110, USA.
Timothy J VickersDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine in Saint Louis, Saint Louis, MO 63110, USA.
Michael G ProutyU.S. Naval Medical Research Unit No. 6-NAMRU 6, Lima 15001, Peru.
Lora L IannottiInstitute for Public Health, Brown School, Washington University in Saint Louis, Saint Louis, MO 63110, USA.
Sherlie Jean Louis DulienceInstitute for Public Health, Brown School, Washington University in Saint Louis, Saint Louis, MO 63110, USA.
James M FleckensteinDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine in Saint Louis, Saint Louis, MO 63110, USA.
Washington University in St. Louis · USNaval Medical Research Unit Six · PEVA St. Louis Health Care System · US

Funding

Washington University Center for Diabetes Translation Research P30DK092950 · NIDDK · WASHINGTON UNIVERSITY · PI Ross C Brownson, Debra Haire-Joshu · 2011 to 2026
$11.7M
Novel Antigen Identification for an Enterotoxigenic E. coli VaccineR01AI089894 · NIAID · WASHINGTON UNIVERSITY · PI Zachary T. Berndsen, James Michael Fleckenstein · 2010 to 2026
$7.4M
Molecular Pathogenesis of enterotoxigenic E. coli associated enteropathyR01AI170949 · NIAID · WASHINGTON UNIVERSITY · PI James Michael Fleckenstein · 2023 to 2026
$2.4M
Accelerating Translational Development of Novel Antigens for an Enterotoxigenic E. coli VaccineK23AI130389 · NIAID · WASHINGTON UNIVERSITY · PI KUHLMANN, FREDERICK M · 2017 to 2021
$807k
Molecular Pathogenesis of Enterotoxigenic Escherichia coli InfectionsI01BX001469 · VA · ST. LOUIS VA MEDICAL CENTER · PI FLECKENSTEIN, JAMES MICHAEL · 2013 to 2017
–
Molecular Pathogenesis of Enterotoxigenic Escherichia coli InfectionsI01BX004825 · VA · ST. LOUIS VA MEDICAL CENTER · PI FLECKENSTEIN, JAMES MICHAEL · 2020 to 2024
–
BLRD VA I01 BX001469BLRD VA I01 BX004825NIAID NIH HHS K23 AI130389NIAID NIH HHS R01 AI089894NIAID NIH HHS R01 AI170949NIDDK NIH HHS P30 DK092950
6 · The paper itself

Abstract

Enterotoxigenic Escherichia coli (ETEC) are common causes of infectious diarrhea among young children of low-and middle-income countries (LMICs) and travelers to these regions. Despite their significant contributions to the morbidity and mortality associated with childhood and traveler's diarrhea, no licensed vaccines are available. Current vaccine strategies may benefit from the inclusion of additional conserved antigens, which may contribute to broader coverage and enhanced efficacy, given their key roles in facilitating intestinal colonization and effective enterotoxin delivery. EatA and EtpA are widely conserved in diverse populations of ETEC, but their immunogenicity has only been studied in controlled human infection models and a population of children in Bangladesh. Here, we compared serologic responses to EatA, EtpA and heat-labile toxin in populations from endemic regions including Haitian children and subjects residing in Egypt, Cameroon, and Peru to US children and adults where ETEC infections are sporadic. We observed elevated IgG and IgA responses in individuals from endemic regions to each of the antigens studied. In a cohort of Haitian children, we observed increased immune responses following exposure to each of the profiled antigens. These findings reflect the wide distribution of ETEC infections across multiple endemic regions and support further evaluation of EatA and EtpA as candidate ETEC vaccine antigens.

Indexed as

antibodiesantigensdiarrheaenterotoxigenic Escherichia colisurfacevaccine

Identifiers

PMID37764065
PMCPMC10536235
OpenAlexW4386380431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.